220 related articles for article (PubMed ID: 31955970)
1. [Use of rituximab in maintenance treatment of pemphigus: A retrospective series].
Barroil M; Girard C; Lerisson M; Negroni V; Bertrand AS; Pallure V; Bessis D; Guillot B; Dereure O
Ann Dermatol Venereol; 2020 Mar; 147(3):173-178. PubMed ID: 31955970
[TBL] [Abstract][Full Text] [Related]
2. Rituximab and low dose oral immune modulating treatment to maintain a sustained response in severe pemphigus patients.
Keeley JM; Bevans SL; Jaleel T; Sami N
J Dermatolog Treat; 2019 Jun; 30(4):340-345. PubMed ID: 30086663
[No Abstract] [Full Text] [Related]
3. Maintenance treatment of pemphigus with rituximab in real life: A single-center study of 50 patients.
Louchez A; El Aarbaoui T; Weill A; Gaudin O; Jelti L; Belmondo T; Wolkenstein P; Ingen-Housz-Oro S
Ann Dermatol Venereol; 2024 Jun; 151(2):103264. PubMed ID: 38537431
[TBL] [Abstract][Full Text] [Related]
4. Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better?
Balighi K; Daneshpazhooh M; Mahmoudi H; Badakhsh M; Teimourpour A; Ehsani AH; Azizpour A; Akbari Z; Mahdavinia M; Ghasemiadl M; Tavakolpour S
Arch Dermatol Res; 2019 Jan; 311(1):63-69. PubMed ID: 30506422
[TBL] [Abstract][Full Text] [Related]
5. Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up.
Reguiai Z; Tabary T; Maizières M; Bernard P
J Am Acad Dermatol; 2012 Oct; 67(4):623-9. PubMed ID: 22261417
[TBL] [Abstract][Full Text] [Related]
6. Rituximab therapy in pediatric pemphigus patients: A retrospective analysis of five Turkish patients and review of the literature.
Bilgic-Temel A; Özgen Z; Harman M; Kapıcıoğlu Y; Uzun S
Pediatr Dermatol; 2019 Sep; 36(5):646-650. PubMed ID: 31355479
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey.
Uzun S; Bilgiç Temel A; Akman Karakaş A; Ergün E; Özkesici B; Eskiocak AH; Erat A; Uğurlu N; Nazlım B; Koç S; Bozkurt S; Dicle Ö; Alpsoy E; Yılmaz E
Int J Dermatol; 2016 Dec; 55(12):1362-1368. PubMed ID: 27653507
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study.
Toosi R; Mahmoudi H; Balighi K; Teimourpour A; Alaeen H; Shaghaghi M; Abedini R; Daneshpazhooh M
J Dermatolog Treat; 2021 Feb; 32(1):33-40. PubMed ID: 31074302
[No Abstract] [Full Text] [Related]
9. Retrospective analysis of a single-center clinical experience toward development of curative treatment of 123 pemphigus patients with a long-term follow-up: efficacy and safety of the multidrug protocol combining intravenous immunoglobulin with the cytotoxic immunosuppressor and mitochondrion-protecting drugs.
Grando SA
Int J Dermatol; 2019 Jan; 58(1):114-125. PubMed ID: 30047585
[TBL] [Abstract][Full Text] [Related]
10. The use of rituximab as an adjuvant in the treatment of oral pemphigus vulgaris.
Fortuna G; Calabria E; Ruoppo E; Adamo D; Aria M; Amato M; Mignogna MD
J Oral Pathol Med; 2020 Jan; 49(1):91-95. PubMed ID: 31420993
[TBL] [Abstract][Full Text] [Related]
11. Multiple cycles of rituximab therapy for pemphigus: A group of patients with difficult- to-treat disease or a consequence of late rituximab initiation?
Balighi K; Hatami P; Sheikh Aboli MJ; Daneshpazhooh M; Ghiasi M; Mahmoudi HR; Aryanian Z
Dermatol Ther; 2022 Feb; 35(2):e15249. PubMed ID: 34910350
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety analysis of rituximab in 146 Indian pemphigus patients: A retrospective single-center review of up to 68 months follow-up.
De D; Bishnoi A; Handa S; Mahapatra T; Mahajan R
Indian J Dermatol Venereol Leprol; 2020; 86(1):39-44. PubMed ID: 31089006
[TBL] [Abstract][Full Text] [Related]
13. Clinical resolution of pemphigus vulgaris on rituximab.
Cusick E; Silverstein D
Dermatol Online J; 2017 Sep; 23(9):. PubMed ID: 29469734
[TBL] [Abstract][Full Text] [Related]
14. Maintenance therapy with azathioprine prolonged duration of remission for pemphigus patients who received rituximab as first-line or add-on therapy.
Cho YT; Huang YM; Wang LF; Chu CY
J Formos Med Assoc; 2020 Jan; 119(1 Pt 2):230-237. PubMed ID: 31103376
[TBL] [Abstract][Full Text] [Related]
15. Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus.
Kushner CJ; Wang S; Tovanabutra N; Tsai DE; Werth VP; Payne AS
JAMA Dermatol; 2019 Dec; 155(12):1404-1409. PubMed ID: 31642878
[TBL] [Abstract][Full Text] [Related]
16. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up.
Ahmed AR; Nguyen T; Kaveri S; Spigelman ZS
Int Immunopharmacol; 2016 May; 34():25-31. PubMed ID: 26919279
[TBL] [Abstract][Full Text] [Related]
17. Pemphigus vulgaris relapse during the coronavirus disease pandemic.
Saleh MA; Saleh NA
Dermatol Ther; 2022 Apr; 35(4):e15354. PubMed ID: 35108427
[TBL] [Abstract][Full Text] [Related]
18. Long-term experience with rituximab therapy for treatment-resistant moderate-to-severe pemphigus.
Bozca BC; Bilgiç A; Uzun S
J Dermatolog Treat; 2022 Jun; 33(4):2102-2109. PubMed ID: 34027788
[TBL] [Abstract][Full Text] [Related]
19. Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: A retrospective analysis.
Agarwal A; Hall RP; Bañez LL; Cardones AR
PLoS One; 2018; 13(9):e0198074. PubMed ID: 30252855
[TBL] [Abstract][Full Text] [Related]
20. Crescendo response to rituximab in oral pemphigus vulgaris: a case with 7-year follow-up.
Greenblatt DT; Benton EC; Groves RW; Setterfield JF
Clin Exp Dermatol; 2016 Jul; 41(5):529-32. PubMed ID: 27061201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
